VERAXA Biotech AG (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (“bsADC”) program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach intended to improve precision in treating solid tumors.
Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue generated from resulting products. This milestone marks a significant step forward in the development of next-generation antibody-based therapeutics.
The advancement of VXA-222 underscores the potential of bispecific ADCs to address limitations of traditional cancer therapies. By targeting two tumor antigens simultaneously, the AND-gate approach may reduce off-target effects and enhance tumor specificity, offering a more precise treatment option for patients with solid tumors. The collaboration leverages OmniAb's advanced antibody discovery capabilities and VERAXA's expertise in linker and conjugation technologies, combining strengths to accelerate the development of novel therapeutics.
For more details, the full press release is available at https://ibn.fm/qMRuJ. VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company's pipeline is rapidly advancing into clinical development, driven by transformative technologies and quality-by-design principles.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company’s proprietary BiTAC technology is a registered trademark of VERAXA Biotech GmbH. Investors can find the latest news and updates regarding VRXA in the company’s newsroom at http://ibn.fm/VRXA.
